BusinessOxford Biomedica Portfolio Grows 34% Despite H1 2026 Revenue Miss
Oxford Biomedica's portfolio increased by 34% in the first half of 2026, even though the company missed its revenue targets during this period. The growth in the portfolio contrasts with the revenue shortfall, highlighting mixed financial results for the biotech firm in H1 2026.
Investing India·2d ago




